Zoya Demidenko: Scientist in Oncology Studies
Zoya Demidenko is a notable scientist connected with the Department of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she conducted research at the National Institutes of Health and New York Medical College, establishing a robust foundation in clinical research.
Demidenko's scientific work encompasses a number of key domains, encompassing the PI3K/AKT/mTOR signaling cascade, cell cycle management, cellular aging, and tumor biology. To date, she has written over 46 academic publications, which have garnered upwards of 4,100 mentions — a reflection to the significance of her research.
Among her key contributions concerns elucidating the pathways of biological cell aging. Her studies revealed that when the cellular division cycle is blocked but cellular growth proceeds, cells enter senescence. Crucially,
Zoya Demidenko established that this process is controlled with drugs using agents such as rapamycin.
Zoya Demidenko has furthermore brought considerably to tumor management research, notably in the domain of cyclotherapy — a approach intended to safeguarding non-cancerous cells from anticancer drugs whilst leaving cancer cells vulnerable. This method holds significant promise for reducing the side effects of cancer treatment.
Across her career, Demidenko has collaborated with prominent investigators internationally, such as Dr. Mikhail Blagosklonny. Her publications is published in prestigious publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33,
Zoya Demidenko stands as a highly impactful contributor in modern cancer research, whose findings keep to guide our knowledge of the way cells grow old, respond to treatment, and the ways in which cancer might be better targeted.
https://www.pinterest.com/zoyademidenko/
